WEST PALM BEACH, FL--(Marketwired - January 07, 2015) -
Highlighted Links |
Medytox Solutions, Inc. |
"Obtaining our laboratory permit in New York State represents a significant market opportunity for Medytox to expand our business," said William DePond, M.D., COO of Medytox Diagnostics. "We're now in a position to offer our testing services to lots of new clients with special focus on the hundreds of substance abuse facilities and pain management practices in the nation's third most populous state."
Medytox's entry into the New York market is one of many major growth initiatives for the company. It recently acquired a California-based laboratory as part of its West Coast expansion, and it launched an electronic health record (EHR) designed for drug and alcohol treatment facilities through another subsidiary, Medytox Information Technology, Inc.
"New York State licensing requirements are perhaps the most stringent in the country, so by getting this license we've demonstrated our labs are all about quality," said Seamus Lagan, CEO of Medytox Solutions, Inc. "Our newly licensed lab is already processing specimens for clients in New York, and is poised for major growth during 2015."
About Medytox Solutions, Inc.
Medytox (OTCBB: MMMS) is a holding company that owns and operates businesses in the medical services sector, including clinical laboratory blood and urine testing services. It operates six laboratories throughout the U.S. with a particular emphasis in the provision of drug toxicology and monitoring pain management programs. Clients include physicians, clinics and rehabilitation facilities throughout the United States.
Help employers find you! Check out all the jobs and post your resume.